comparemela.com

Latest Breaking News On - Drug development pipeline - Page 3 : comparemela.com

US Dermatologic Drug Approvals Rose Between 2012 and 2022

Roche Joins Race for Obesity Drugs With $2 7 Billion Carmot Deal

Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.

FDA Panel Flags Insufficient Data for Chronic Cough Drug

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.